SCHEMBL6349745

SCHEMBL6349745

COc1cccc(C(=O)CN(C(=O)c2ccccc2)C(C(N)=O)C(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.54
PARP1 P09874 1/20 0.47
HSD11B1 P28845 1/20 0.46
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
DRD1 P21728 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
ADRA1A P35348 1/20 0.45
OPRM1 P35372 1/20 0.45
DRD3 P35462 1/20 0.45
SLC6A3 Q01959 1/20 0.45
KCNH2 Q12809 1/20 0.45
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6347549 0.91 HSD11B1 (0.48) TRPM8PARP1HSD11B1HTR1AADRA2A
SCHEMBL6356063 0.88 L3MBTL1 (0.49) TRPM8HSD11B1OPRM1NPC1RAB9A
SCHEMBL6352526 0.88 PARP1 (0.49) TRPM8PARP1HSD11B1HTR1AADRA2A
SCHEMBL6358312 0.86 CTNNB1 (0.45) HTR1AADRA1AKCNH2NPC1RAB9A
SCHEMBL6350864 0.85 TRPM8 (0.47) TRPM8ALDH1A1LMNAMAPK1TDP1
SCHEMBL6359179 0.85 TRPM8 (0.47) TRPM8ALDH1A1LMNAMAPK1TDP1
SCHEMBL6359355 0.83 TP53 (0.42) TRPM8ALDH1A1LMNAMAPK1HTT
SCHEMBL6358599 0.80 HSD11B1 (0.46) PARP1HSD11B1HTR1AADRA2ADRD1
SCHEMBL6351225 0.79 CYP3A4 (0.47) TRPM8NPC1RAB9AALDH1A1L3MBTL1
SCHEMBL6359454 0.79 CYP3A4 (0.47) TRPM8NPC1RAB9AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 TRPM8 1934/4885PARP1 4510/4885HSD11B1 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.